Patents Represented by Attorney, Agent or Law Firm Deborah A. Sawislak
  • Patent number: 6171822
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for stanniocalcin-2, a novel member of the stanniocalcin family. The polypeptides, and polynucleotides encoding them, modulate electrolyte homeostasis. The present invention also includes antibodies to the stanniocalcin-2 polypeptides.
    Type: Grant
    Filed: October 11, 1999
    Date of Patent: January 9, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Rolf E. Kuestner, Darrell C. Conklin, Si Lok, Michele Buddle, William Downey
  • Patent number: 6143720
    Abstract: The present invention is directed to polynucleotides and polypeptides for a novel member of the lipocalin family. The expression of this novel polynucleotide is restricted to testis and mammary gland, particularly breast tumor tissue. The polypeptide has been designated zlipo1. The present invention also includes antibodies to the zlipo1 polypeptides.
    Type: Grant
    Filed: November 2, 1999
    Date of Patent: November 7, 2000
    Assignee: ZymoGenetics, Inc.
    Inventor: Darrell C. Conklin
  • Patent number: 6114307
    Abstract: The present invention provides compositions for stimulating an increase in islet proliferation and .beta.-cell mass using an insulin homolog polypeptide. The present invention also includes methods for treating diabetes by stimulating islet proliferation and .beta.-cell mass increases and affecting insulin levels.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: September 5, 2000
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Katherine H. Sprugel, Hong Ping Ren, Jacqueline M. Humes, Darrell C. Conklin
  • Patent number: 6099830
    Abstract: Methods for stimulating erythropoiesis using the hematopoietic protein thrombopoietin, optionally in combination with erythropoietin, are provided. The methods provided may be used to stimulate erythropoiesis in bone marrow and peripheral blood cells and in vitro and in vivo. In addition, methods for treatment of thrombocytopenia and anemia in patients are disclosed.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: August 8, 2000
    Assignees: ZymoGenetics, Inc., University of Washington
    Inventor: Kenneth Kaushansky
  • Patent number: 6084088
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for a secreted polypeptide designated zsig15. The polypeptides, and polynucleotides encoding them, may be used for mapping chromosome 19 and markers for tumor growth. The present invention also includes antibodies to the zsig15 polypeptides.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: July 4, 2000
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Angelika Grossmann
  • Patent number: 6046028
    Abstract: The present invention relates to polynucleotides encoding for novel insulin homolog polypeptides that have been designated Zins3. The human and mouse polynucleotides and corresponding polypeptides are described, and comprise a B chain, A chain, and C-peptide, or portions thereof. The polynucleotide sequence maps to human chromosome 12.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: April 4, 2000
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Catherine E. Lofton-Day, Si Lok, Stephen R. Jaspers
  • Patent number: 6020163
    Abstract: The present invention is directed to polynucleotides and polypeptides for a novel member of the lipocalin family. The expression of this novel polynucleotide is restricted to testis and mammary gland, particularly breast tumor tissue. The polypeptide has been designated zlipo1. The present invention also includes antibodies to the zlipo1 polypeptides.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: February 1, 2000
    Assignee: ZymoGenetics, Inc.
    Inventor: Darrell C. Conklin
  • Patent number: 6008322
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for stanniocalcin-2, a novel member of the stanniocalcin family. The polypeptides, and polynucleotides encoding them, modulate electrolyte homeostasis. The present invention also includes antibodies to the stanniocalcin-2 polypeptides.
    Type: Grant
    Filed: April 1, 1997
    Date of Patent: December 28, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Rolf E. Kuestner, Darrell C. Conklin, Si Lok, Michele Buddle, William Downey
  • Patent number: 5989866
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zFGF-5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells and may be used for remodelling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF-5 polypeptides.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: November 23, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Theresa A. Deisher, Darrell C. Conklin, Fenella Raymond, Thomas R. Bukowski, Susan D. Holderman, Birgit Hansen, Paul O. Sheppard
  • Patent number: 5989537
    Abstract: Methods for stimulating granulocyte/macrophage lineage cells using thrombopoiet in are provided. The methods provided may be used to stimulate granulocyte/macrophage progenitors and neutrophils in bone marrow and peripheral blood cells and in vitro and in vivo. In addition, methods for treatment of neutropenia in patients are disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 23, 1999
    Assignees: ZymoGenetics, Inc., University of Washington
    Inventors: Richard D. Holly, Si Lok, Donald C. Foster, Frederick S. Hagen, Kenneth Kaushansky, Joseph L. Kuijper, Catherine E. Lofton-Day, Pieter J. Oort
  • Patent number: 5959075
    Abstract: The present invention provides testis-specific insulin homolog polypeptides and polynucleotides encoding the polypeptides, as well as related compositions and methods are disclosed. The polypeptides and polynucleotides may be used within methods for enhancing viability of cryopreserved sperm, for enhancing sperm motility, to enhance fertilization in methods of assisted reproduction, as contraceptives and other related uses.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: September 28, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Si Lok, Darrell C. Conklin, Robyn L Adams, Anna C. Jelmberg, Catherine E. Lofton-Day, Stephen R. Jaspers
  • Patent number: 5914315
    Abstract: The present invention provides isolated DNA molecules comprising a DNA segment encoding novel human Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human Kunitz-type inhibitor wherein first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: June 22, 1999
    Assignees: Zymogenetics, Inc., University of New Mexico
    Inventors: Cindy A. Sprecher, Walt Kisiel, Donald C. Foster
  • Patent number: 5905185
    Abstract: Methods for producing protein C in transgenic non-human mammals are disclosed. The protein C is modified at the two-chain cleavage site between the light and heavy chains of protein C from Lys-Arg to R.sub.1 -R.sub.2 -R.sub.3 -R.sub.4 where R.sub.1 through R.sub.4 are individually Arg or Lys. DNA segments encoding modified protein C are introduced into the germ line of a non-human mammals, and the mammal or its female progeny produces milk containing protein C expressed from the introduced DNA segments. The protein C expressed from the introduced DNA segments has anticoagulant activity when activated. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous protein C are also disclosed.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: May 18, 1999
    Assignees: PPL Therapeutics, ZymoGenetics, Inc.
    Inventors: Ian Garner, Ian R. Cottingham, Simon M. Temperley, Donald C. Foster, Cindy A. Sprecher, Donna E. Prunkard
  • Patent number: 5683906
    Abstract: Cell lines have been prepared from growth suppressor gene deficient animals. The cells include immortalized precursor cells and differentiated cells such as osteoclast precursors, osteoblast precursors, megakaryocytes, osteoclasts, osteoblasts, pancreatic .alpha.-cells, pancreatic .beta.-cells, pancreatic .delta.-cells, adipocytes, macrophages, chondrocytes and hepatocytes. The cells are useful for constructing cDNA and protein libraries, screening agonists and antagonists of compounds and factors that affect metabolic pathways of specific cells and generating cell-specific antibodies.
    Type: Grant
    Filed: September 9, 1994
    Date of Patent: November 4, 1997
    Assignee: ZymoGenetics, Inc.
    Inventor: Emma E. Moore
  • Patent number: 5648219
    Abstract: The present invention provides an immature dendritic cell line derived from p53 growth suppressor gene deficient animals. The immature dendritic cell line may be induced to become an activated dendritic cell line that will stimulate T-cells to proliferate. The cell line is useful for presentation of antigens involved in autoimmune disease and analysis of peptides that produce a T-cell response.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 15, 1997
    Assignee: ZymoGenetics, Inc.
    Inventors: Vivian L. MacKay, Emma E. Moore
  • Patent number: 5646285
    Abstract: The present invention relates to an orthogonally-protected compound of the formula: ##STR1## wherein PG.sub.1 is a first protecting group that is unreactive to a chemistry used at another position within the compound, and that is capable of selective removal without affecting PG.sub.2 or linkage to a solid support; PG.sub.2 is a second protecting group that is unreactive to a chemistry used at another position within the compound, and that is capable of selective removal without affecting PG.sub.1 or linkage to a solid support; Y is CH.sub.2 COOH, CH.sub.2 SO.sub.2 OH, CH.sub.2 PO.sub.2 ROH, CH.sub.2 Ph--COOH, CH.sub.2 Ph--SO.sub.2 OH, or CH.sub.2 Ph--PO.sub.2 ROH; R is H or a substituted or unsubstituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; and n is 1 or 2. PG.sub.1 is preferably a carbamate group, a trityl group, or a trifluoroacetyl group; and PG.sub.2 is preferably an ester.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 8, 1997
    Assignee: ZymoGenetics, Inc.
    Inventors: Nand Baindur, Virender M. Labroo
  • Patent number: 5641655
    Abstract: DNA constructs useful in the production of thrombopoietin are disclosed. In general, the DNA constructs comprise a first DNA segment encoding a fusion of an amino-terminal secretory peptide joined to a thrombopoietin polypeptide and one or more additional DNA segments that provide for the transcription of the first segment. The secretory peptide is a native mammalian t-PA secretory peptide or may be modified to enhance proteolytic cleavage of the fusion. Also disclosed are cultured eukaryotic cells containing these DNA constructs and methods for producing thrombopoietin polypeptides through the use of the DNA constructs and cultured eukaryotic cells.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: June 24, 1997
    Assignee: ZymoGenetics, Inc.
    Inventors: Donald C. Foster, Mark D. Heipel, Richard D. Holly
  • Patent number: 5639940
    Abstract: Materials and methods for producing fibrinogen in transgenic non-human mammals are disclosed. DNA segments encoding A.alpha., B.beta. and .gamma. chains of fibrinogen are introduced into the germ line of a non-human mammal, and the mammal or its female progeny produces milk containing fibrinogen expressed from the introduced DNA segments. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous fibrinogen polypeptide chains are also disclosed.
    Type: Grant
    Filed: March 3, 1994
    Date of Patent: June 17, 1997
    Assignees: Pharmaceutical Proteins Ltd., ZymoGenetics, Inc.
    Inventors: Ian Garner, Michael L. Dalrymple, Donna E. Prunkard, Donald C. Foster
  • Patent number: 5622843
    Abstract: Isolated polynucleotide molecules encoding mammalian phospholipid transfer proteins (PLTP) and phospholipid transfer protein polypeptides are disclosed. The DNA molecules are transformed or transfected into host cells and the cells cultured to produce recombinant PLTP and PLTP polypeptides. PLTP and PLTP polypeptides may be combined with a pharmaceutically acceptable vehicle and administered to patients to regulate phospholipid transfer activity and thereby obtain a more favorable lipoprotein profile in the blood. The proteins and polypeptides may also be used within methods to measure phospholipid transfer activity or identify inhibitors of phospholipid transfer activity.
    Type: Grant
    Filed: December 30, 1993
    Date of Patent: April 22, 1997
    Assignees: Zymogenetics, Inc., University of Washington
    Inventors: Joseph R. Day, John J. Albers, Catherine E. Lofton-Day, Janet L. Adolphson
  • Patent number: 5620687
    Abstract: Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal an anti-PDGF receptor antibody, such as an anti-PDGF-alpha receptor antibody or an anti-PDGF-beta receptor antibody. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The anti-PDGF receptor antibodies may optionally be administered coordinately with heparin, whereby the coordinately administered antibody and heparin are combinatorially effective in inhibiting intimal hyperplasia.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: April 15, 1997
    Assignees: ZymoGenetics, Inc., University of Washington
    Inventors: Charles E. Hart, Richard D. Kenagy, Alexander W. Clowes